Managing Discovery in the Life Sciences: Harnessing Creativity to Drive Biomedical Innovation
Cambridge University Press, 2/1/2018
EAN 9781107577305, ISBN10: 1107577306
Paperback, 554 pages, 23.4 x 16.4 x 2.4 cm
Language: English
In this book, distinguished scholars Philip A. Rea, Mark V. Pauly, and Lawton R. Burns explore the science and management behind marketable biomedical innovations. They look at how the science actually played out through the interplay of personalities, the cultures within and between academic and corporate entities, and the significance of serendipity not as a mysterious phenomenon but one intrinsic to the successes and failures of the experimental approach. With newly aggregated data and case studies, they consider the fundamental economic underpinnings of investor-driven discovery management, not as an obstacle or deficiency as its critics would contend or as something beyond reproach as some of its proponents might claim, but as the only means by which scientists and managers can navigate the unknowable to discover new products and decide how to sell them so as to maximize the likelihood of establishing a sustainable pipeline for still more marketable biomedical innovations.
Preface
1. Discoveries now and then
shifting incentives and expectations Mark V. Pauly, Philip A. Rea and Lawton R. Burns
2. Pharma trends
not what they seem Kyle Myers and Mark V. Pauly
3. Profit maximizing drug firms
models and myths Vicki Chen and Mark V. Pauly
Transitional note
introduction to the case studies
4. The Statins
cholesterols 'penicillins' Philip A. Rea
5. ACE inhibitors
kidney clamps, snake venoms and peptidomimetics Alec Ren and Philip A. Rea
6. Angioplasty
catheters, guidewires and balloons Simon Basseyn, Sourav Bose, Lawton R. Burns and Chris Groskaufmanis
7. Hepatitis C
when cures and prices go viral Stephen Goldstein, Peter M. Stokes, Connie Lu and Philip A. Rea
8. Alzheimer's
America's new most feared disease Julian Pei, John Q. Trojanowski, Peter M. Stokes, Katherine Clark, Mark V. Pauly and Philip A. Rea
9. Metformin
to the brink and back Anderson Y. Tien and Philip A Rea
10. Medical genomics
personalized precision Marc S. Williams
11. Gleevec
from broken chromosomes to precision cancer therapy Vivek Nimgaonkar and Philip A. Rea
12. Regeneron
agility, resilience and balance Lawton R. Burns, Alex Rosen, Steven Nichtberger and Philip A. Rea
13. Avastin and Lucentis
both for eyesight in hindsight Osama Ahmed, Mark V. Pauly, Peter M. Stokes and Philip A. Rea
14. CAR T-cell therapy
cures for ALL and more? Stephen Goldstein, Amy Le and Philip A. Rea
15. Organizing discovery
wild ducks nested in multilevel ecosystems Lawton R. Burns and Philip A. Rea
16. Can government help with the creatively unexpected? Mark V. Pauly, Lawton R. Burns and Philip A. Rea
Appendix
three key elements in the discovery process
historical and philosophical antecedents Mark V. Pauly
Index.